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peripheral blood upon recovery of neutrophils. If peripheral
blood CD34 count was below 10/microL, Plerixafor 0.24 mg/
kg/day with or without Neupogen 10mcg/kg/day was added.
Absolute pre CD34 values prior to Plerixafor ranged from
0e6. Pre CD34 values after Plerixafor ranged from 6 - 303.
Target CD34 yield per kg for NHL/HL patients was 2-5 X 106.
Target CD34 yield per kg for MM patients was 5-10 X 106.
Following this intervention 11 patients were able to
successfully complete stem cell mobilization and achieve
target yields. 2 MM patients did not meet the collection goal
for 2 transplants but did have sufﬁcient yield for one. Median
total CD34 yield per kg was 6.9 X 106. Mean total CD34 yield
for NHL/HL pts was 6.17 X 106 per kg. Mean total CD34 yield
for MMpts was 10.59 X 106 per kg. Mean total MNC yield was
14.23 X 108 per kg for NHL/HL pts. Mean total MNC yield was
8.71 X 108 per kg for MM pts. Average time for neutrophil
engraftment was 11.46 days. Average time for platelet
engraftment was 19.91 days. There were no major compli-
cations associated with the above combination and no
unanticipated side effects.
Combination of Plerixafor and Filgrastim can be safely and
successfully administered to patients with inadequate
peripheral blood pre-CD34 counts following chemotherapy
based mobilization regimens. This will prevent delay in the
transplantation process.131
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Background: Over 400 cases of pediatric severe aplastic
anemia (SAA) occur annually in the United States. A growing
number of children with SAA may have had their stem cells
harvested through cord blood collection. We describe a 9-
year-old male with SAA treated successfully with an autol-
ogous cord blood transplant following immunoablative
chemotherapy. With increasing numbers of cord blood
cryopreservations, the use of autologous cord blood in the
treatment of SAA might be considered as initial therapy.
Methods: A previously healthy 9-year-old Hispanic malewas
diagnosed with acquired SAA. Due to ongoing transfusion
support, and the lack of a sibling donor, anti-thymocyte
globulin and cyclosporine was initiated. Six months
following the start of immunosuppressive therapy, the
patient had no marrow recovery. An unrelated bone marrow
donor search revealed one 9 out of 10 matched unrelated
bonemarrow donor (HLA A antigenmismatch). One 10 out of
10 matched cord blood unit was available in the public cord
blood registry and further inquiry revealed that this donated
cord blood unit was an autologous unit. Given the lack of
response to immunosuppressive therapy, the risks associated
with the use of a mismatched unrelated donor hematopoi-
etic cell transplantation (HCT), and the availability of the
patients own cord blood unit, a decision was made to
proceed with autologous cord blood HCT.Results: The HCT preparative regimen included: ﬂudarabine
30 mg/m2/day from Day -6 to Day -4 for a total dose of 90
mg/m2. Cyclophosphamide 60 mg/kg/day was given from
Day -3 to Day -2 for a total dose of 120 mg/kg together with
MESNA prophylaxis. This was followed by a day of rest on
Day -1 and an infusion of 3.0 x 10e7 TNC/kg and 0.9 x 10e6
CD34+ /kg using an autologous cord blood unit on Day 0. His
absolute neutrophil count exceeded 500 cell/uL on Day + 21
and has subsequently remained above this threshold
without growth factor support. His platelet count was
greater than 20,000 /uL on Day + 36 with his last platelet and
packed red blood cell transfusion given on Day +20. The
patient was discharged at Day +27 and remains transfusion
independent at the time of his most recent clinical assess-
ment at Day +100. His Lansky performance status was 100 at
discharge and has remained so now at over 3 months
following transplant.
Conclusion: To our knowledge, this is the ﬁrst description of
a successful application of autologous cord blood HCT in
a pediatric patient with acquired SAA using an immunoa-
blative preparative regimen consisting of ﬂudarabine and
cyclophosphamide. We found autologous cord blood HCT
following an immunoablative combination of ﬂudarabine
and cyclophosphamide to be an effective and safe alternative
to the potential complications as well as morbidity and
mortality associated with the use of matched unrelated
donor HCT or the use of other alternative donor HCT
approaches.132
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Background: Engraftment syndrome (ES), characterized by
noninfectious fever, rash, diarrhea, and/or respiratory
symptoms during engraftment, can be associated with
increased morbidity and resource utilization (e.g., IV antibi-
otics, hospitalization) after autologous stem cell transplant
(ASCT). ES remains a clinical diagnosis, without conﬁrmed
biomarkers or standardized treatment recommendations.
Herein, we describe the clinical, laboratory, and outcomes
data from a large contemporary cohort of ASCT recipients
and suggest new diagnostic criteria.
Methods: 526 consecutive patients who underwent ASCT at
Mayo Clinic from 1/1/2009-12/31/2010 were included.
Diseases included: multiple myeloma, 48%; NHL, 30%;
amyloidosis, 12%; HL, 7%; and POEMS, 2%. Mayo Clinic criteria
for ES was deﬁned by a noninfectious fever of 38.3C from 4d
prior to WBC 500/ul up until ANC 500/ul and at least one of
the following: rash (erythematous with >25% trunk
involvement), diarrhea (>3 loose stools/d), or pulmonary
